

Substitute Form PTO-1449
(Modified)U.S. Department of Commerce
Patent and Trademark OfficeAttorney's Docket No.
12938-002001Application No.
09/812,945

Information Disclosure Statement

Applicant

(Use several sheets if necessary)

Applicant

Hsuan-Yin Lan-Hargest et al.

Filing Date

March 27, 2001

Group Art Unit

(37 CFR §1.98(b))

U.S. Patent Documents

Examiner Initial	Desig. ID	Patent Number	Issue Date	Patentee	Class	Subclass	Filing Date If Appropriate
<i>MB</i>	BB	5,710,178	01-20-1998	Samid			
	BC	5,705,167	01-06-1998	Bernardon et al.			
	BD	5,696,162	12-09-1997	Chandraratna			
	BE	5,688,819	11-18-1997	Woodward et al.			
	BF	5,677,320	10-14-1997	Chandraratna			
	BG	5,672,746	09-30-1997	Nau et al.			
	BH	5,643,949	07-01-1997	Van Scott et al.			
	BI	5,607,978	03-04-1997	Woodward et al.			
	BJ	5,602,135	02-11-1997	Chandraratna			
	BK	5,547,988	08-20-1996	Yu et al.			
	BL	5,541,155	07-30-1996	Leone-Bay et al.			
	BM	5,525,629	06-11-1996	Crimmin et al.			
	BN	5,486,540	01-23-1996	Andrews			
	BO	5,475,022	12-12-1995	Chandraratna			
	BP	5,466,718	11-14-1998	Nakatsu et al.			
	BQ	5,420,160	05-30-1995	Gayer et al.			
	BR	5,385,942	01-31-1995	Abe et al.			
	BS	5,369,108	11-29-1994	Breslow et al.			
	BT	5,320,833	06-14-1994	Deckers et al.			
	BU	5,272,180	12-21-1993	Hashimoto et al.			
	BV	5,264,424	11-23-1993	Della Valle et al.			
	BW	5,246,955	09-21-1993	Skibo et al.			
	BX	5,244,922	09-14-1993	Burzynski			
	BY	5,235,068	08-10-1993	Minai et al.			
	BZ	5,141,959	08-25-1992	Carroll et al.			
	CA	5,112,846	05-12-1992	Belliotti et al.			
<i>MB</i>	CB	5,091,569	02-25-1992	Matsumoto et al.			

Examiner Signature

Date Considered

11/05/01

EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute Form PTO-1449
(Modified)U.S. Department of Commerce
Patent and Trademark OfficeAttorney's Docket No.
12938-002001Application No.
09/812,945**Information Disclosure Statement
by Applicant**

(Use several sheets if necessary)

(37 CFR §1.98(b))

Applicant
Hsuan-Yin Lan-Hargest et al.Filing Date
March 27, 2001

Group Art Unit

U.S. Patent Documents

Examiner Initial	Desig. ID	Patent Number	Issue Date	Patentee	Class	Subclass	Filing Date If Appropriate
MJD	CC	5,089,524	02-18-1992	Collins et al.			
	CD	5,084,214	01-28-1992	Kita et al.			
	CE	5,075,330	12-24-1991	Belliotti et al.			
	CF	5,064,860	11-12-1991	Mueller et al.			
	CG	5,028,629	07-02-1991	Hite et al.			
	CH	4,985,436	01-15-1991	Pettit			
	CI	4,981,865	01-01-1991	Belliotti et al.			
	CJ	4,950,467	08-21-1990	Phalangas et al.			
	CK	4,833,257	05-23-1989	Pettit et al.			
	CL	4,820,828	04-11-1989	Demers et al.			
	CM	4,791,133	12-13-1988	Djuric et al.			
	CN	4,753,934	06-28-1988	Nickl et al.			
	CO	4,731,382	03-15-1988	Zusi et al.			
	CP	4,722,939	02-02-1988	Loev et al.			
	CQ	4,709,076	11-24-1987	Bombardelli et al.			
	CR	4,699,920	10-13-1987	Skuballa et al.			
	CS	4,638,011	01-20-1987	Das			
	CT	4,623,661	11-18-1986	Summers, Jr.			
	CU	4,621,099	11-04-1986	Loev et al.			
	CV	4,619,945	10-28-1986	Loev et al.			
	CW	4,608,390	08-26-1986	Summers, Jr.			
	CX	4,607,053	08-19-1986	Karanewsky et al.			
	CY	4,605,669	08-12-1986	Summers, Jr.			
MK	DA	4,604,407	08-05-1986	Haslanger et al.			
	DB	4,564,476	01-14-1986	Ho			
	DC	4,545,984	10-08-1985	Möller et al.			
	DD	4,534,979	08-13-1985	Loev et al.			

Examiner Signature

Date Considered

11/05/01

EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



Substitute Form PTO-1449 (Modified) Information Disclosure Statement by Applicant (Use several sheets if necessary) (37 CFR §1.98(b))	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 12938-002001	Application No. 09/812,945
	Applicant Hsuan-Yin Lan-Hargest et al.		
	Filing Date March 27, 2001		Group Art Unit

U.S. Patent Documents							
Examiner Initial	Desig. ID	Patent Number	Issue Date	Patentee	Class	Subclass	Filing Date If Appropriate
<i>W</i>	DE	4,505,930	03-19-1985	Loev et al.			
	DF	4,504,494	03-12-1985	Grollier et al.			
	DG	4,472,430	09-18-1984	Loev et al.			
	DH	4,440,940	04-03-1984	Shepherd			
	DI	4,439,443	03-27-1984	Giroux			
	DJ	4,388,459	06-14-1983	Shepherd			
	DK	4,371,614	02-01-1983	Anderson et al.			
	DL	4,355,168	10-19-1982	Chiusoli et al.			
	DM	4,335,054	06-15-1982	Blaser et al.			
	DN	4,309,407	01-05-1982	Lautenschläger et al.			
	DO	4,309,357	01-05-1982	Chiusoli et al.			
	DP	4,288,253	09-08-1981	Venable			
	DQ	4,258,057	03-24-1981	Bartmann et al.			
	DR	4,211,783	07-08-1980	Shepherd			
	DS	4,193,931	03-18-1980	Loeliger			
	DT	4,188,338	02-12-1980	Bruins et al.			
	DU	4,171,318	10-16-1979	Chan et al.			
	DV	4,130,653	12-19-1978	Giroux et al.			
	DW	4,127,723	11-28-1978	Yankee			
	DX	4,127,722	11-28-1978	Lafon			
	DY	4,116,975	09-26-1978	Klaus et al.			
	DZ	4,113,858	09-12-1978	Hashim			
	EA	4,081,476	03-28-1978	Anderson et al.			
	EB	4,061,656	12-06-1977	Klaus et al.			
	EC	4,048,332	09-13-1977	Adams et al.			
	ED	4,044,149	08-23-1977	Fields et al.			
<i>W</i>	EE	4,024,182	05-17-1977	Kathawala			

Examiner Signature <i>[Signature]</i>	Date Considered <i>11/05/01</i>
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Substitute Form PTO-1449 (Modified) Information Disclosure Statement by Applicant (Use several sheets if necessary) (37 CFR §1.98(b))	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 12938-002001	Application No. 09/812,945
	Applicant Hsuan-Yin Lan-Hargest et al.		
	Filing Date March 27, 2001	Group Art Unit	

U.S. Patent Documents


Examiner Initial	Desig. ID	Patent Number	Issue Date	Patentee	Class	Subclass	Filing Date If Appropriate
MS	EF	4,011,339	03-08-1977	Galantay et al.			
	EG	3,984,440	10-05-1976	Bollag et al.			
	EH	3,978,100	08-31-1976	Fujita et al.			
	EI	3,909,353	09-30-1975	Tsuchida et al.			
	EJ	3,886,278	05-27-1975	Gallo			
	EK	3,781,314	12-25-1973	Bollag et al.			
	EL	3,755,604	08-28-1973	Gallo			
	EM	3,687,955	08-29-1972	Cerbati et al.			
	EN	3,674,884	07-04-1972	Moritani et al.			
	EO	3,624,127	11-30-71	Shaw et al.			
	EP	3,551,574	12-29-1970	Frohberger et al.			
	EQ	3,479,396	11-18-1969	Buu-Hoi et al.			
	ER	2,840,586	06-24-1958	Inhoffen			
MS	ES	2,680,755	06-08-1954	Robeson et al.			

Foreign Patent Documents or Published Foreign Patent Applications

Examiner Initial	Desig. ID	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation	
							Yes	No
MS	ET	EP 0 199 151	10-29-1986	European				
	EU	EP 0 161 939	11-21-1985	European				
	EV	WO 01/18171	03-15-2001	WIPO				
MS	EW	WO 01/38322	05-31-2001	WIPO				

Other Documents (include Author, Title, Date, and Place of Publication)

Examiner Initial	Desig. ID	Document
MS	EX	Andrews et al., "Anti-malarial effect of histone deacetylation inhibitors and mammalian tumour cytodifferentiating agents", International Journal for Parasitology, 30, pp. 761-768, (2000).
MS	EY	Collins et al., "Oral Sodium Phenylbutyrate Therapy in Homozygous β Thalassemia: A Clinical Trial", Blood, Vol. 85, No. 1, pp. 43-49, (1995).

Examiner Signature 	Date Considered 11/13/01
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	



Substitute Form PTO-1449 (Modified) Information Disclosure Statement by Applicant (Use several sheets if necessary) (37 CFR §1.98(b))	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 12938-002001	Application No. 09/812,945
	Applicant Hsuan-Yin Lan-Hargest et al.		
	Filing Date March 27, 2001	Group Art Unit	

Other Documents (include Author, Title, Date, and Place of Publication)		
Examiner Initial	Desig. ID	Document
MD	EZ	Finnin et al., "Structures of a histone deacetylase homologue bound to the TSA and SAHA inhibitors", Nature, Vol. 401, pp 188-193, (1999).
	FA	Fruehauf et al., "In Vitro Determination of Drug Response: A Discussion of Clinical Applications", Principles & Practice of Oncology, Vol. 7 No. 12, pp. 1-16, (1993).
	FB	Gore et al., "Modifying histones to tame cancer: clinical development of sodium phenylbutyrate and other histone deacetylase inhibitors", Exp. Opin. Invest. Drugs, 9(12), pp. 2923-2934, (2000).
	FC	Hoffman et al., "A non-isotopic assay for histone deacetylase activity", Nucleic Acids Research, Vol. 27, No. 9, pp. 2057-2058, (1999).
	FD	Kemp et al., "Gene redundancy and pharmacological gene therapy: Implications for X-linked adrenoleukodystrophy", Nature Medicine, Vol. 4, No. 11, pp. 1261-1268, (1998).
	FE	Kim et al., "Oxamflatin is a novel antitumor compound that inhibits mammalian histone deacetylase", Oncogene, Vol. 18, pp. 2461-2470, (1999).
	FF	Marks et al., "Histone Deacetylase Inhibitors: Inducers of Differentiation or Apoptosis of Transformed Cells", Journal of the National Cancer Institute, Vol. 92, No. 15, pp. 1210-1216, (2000).
	FG	Remiszewski et al., "Synthesis and in Vitro SAR of Straight Chain Hydroxamate Histone Deacetylase Inhibitors", Proceedings of the AACR, Vol. 42, No. 4976, (Feb. 27, 2001).
	FH	Rubenstein et al., "In Vitro Pharmacologic Restoration of CFTR-mediated Chloride Transport with Sodium 4-Phenylbutyrate in Cystic Fibrosis Epithelial Cells Containing ΔF508-CFTR", J. Clin. Invest., Vol. 100, No. 10, pp. 2457-2465, (1997).
	FI	Sandler et al., "Organic Functional Group Preparations", Academic Press, New York and London, Vol. III, pp. 436-437, (1972).
	FJ	Saunders et al., Histone deacetylase inhibitors: novel anticancer agents", Exp. Opin. Invest. Drugs, 8(10), pp. 1611-1621, (1999).
W	FK	Taunton et al., "A Mammalian Histone Deacetylase Related to the Yeast Transcriptional Regulator Rpd3p", Science, Vol. 272, pp. 408-411, (1996).

Examiner Signature 	Date Considered 11/07/01
EXAMINER: Initials/Date considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	